Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics

IP: Juan Ignacio Esteban Mur
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 135700
Reference: QLK2-2000-00836
Duration: 01/12/2000 - 01/12/2003

CIBER Enfermedades hepáticas y digestivas (CIBEREHD)

IP: Juan Ignacio Esteban Mur
Collaborators: Josep Quer Sivila
Funding agency: CIBER Enfermedades Hepáticas y Digestivas
Funding:
Reference: CB06/04/0028
Duration: 01/01/2007 - 31/12/2010

Selección y expansión de linfocitos CD4+NS3-específicos de pacientes VHC. caracterización del estado de anergia en cronicidad y restauración funcional para empleo en inmunoterapia adaptativa para prevención y tratamiento de la recurrencia postrasplante.

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Juan Ignacio Esteban Mur
Funding agency: Instituto de Salud Carlos III
Funding: 113740
Reference: PI061244
Duration: 01/01/2007 - 30/12/2009

Seleción y expansión de linfocitos T CD4+NS3-específicos de pacientes coinfectados por VIH y VHC. caracterización del estado de anergia en la infección crónica y restauración funcional para su empleo en inmunoterapia adaptativa para la prevención y/o tra

IP: Juan Ignacio Esteban Mur
Collaborators: Josep Quer Sivila
Funding agency: Fundación Innov. y Prosp. Salud en España - FIPSE
Funding: 85800
Reference: FIPSE/36623/06
Duration: 01/12/2006 - 30/11/2009

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Montserrat Aguilera Pujabet

Montserrat Aguilera Pujabet

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Olga Vallès Frutuoso

Olga Vallès Frutuoso

Research technician
Multidisciplinary Nursing Research Group
Read more
Ximena Garcia Torres

Ximena Garcia Torres

Administration and Management
Translational Molecular Pathology
Read more
Francesc Rudilla Salvador

Francesc Rudilla Salvador

Senior researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.